Uroxatral
(Alfuzosin)ApprovedSmall molecule
Alfuzosin is used to treat urinary symptoms caused by an enlarged prostate gland in men, such as difficulty urinating and frequent urination.[2] Uroxatral is currently approved and in use across 9 indications[4].[1]
Uroxatral is one of 103 small molecule programs targeting Prostate Disease. It is currently in Approved.
9
Indications
31
Total Trials
0
Active Trials
102
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
53 competitors in Erectile Dysfunction
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Levitra
BayerApproved
Viagra
VViatris Specialty LLC
Approved
Rifadin
SanofiApproved
Cipro
BayerApproved
Flomax
SanofiApproved
Avandia
Jazz PharmaceuticalsApproved
Norvir
AbbVieApproved
Avelox
BayerApproved
Caverject
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Benign Prostatic Hyperplasia6 trials
Lower Urinary Tract Symptom3 trials
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
Completed·—·Phase 4·NCT00696761·232 enrolled
Urinary retention2 trials
Treatment2 trials
14 more indications
Chronic Prostatitis1 trial
Hydronephrosis1 trial
Kidney Stones1 trial
Erectile Dysfunction1 trial
Mydriasis1 trial
Hypertrophy1 trial
Randomized1 trial
Regulatory
FDA Approval Timeline[5]
Jun 12, 2003
UROXATRAL
NDA NDA021287
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Uroxatral drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alfuzosin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Adrenergic Receptor Alpha-1 Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAdvanz Pharma